Search results for "Neurologi"

showing 10 items of 1189 documents

Quantitative EEG differentiates multiple sclerosis with and without cognitive impairment from healthy controls at the beginning of the disease: preli…

2018

Background and aims: The present study aims to assess possible qEEG differences between newly diagnosed multiple sclerosis (MS) patients with or without cognitive impairment (CI). Methods: We enrolled 22 patients (18-55-years-old) treated with first-line drugs for <6 months, and 11 healthy controls. All subjects underwent neuropsychological assessment including BICAMS and BDI. EEG recordings were performed during a cognitive task (computerised “SDMT” subtest of BICAMS) and at rest. Based on neuropsychological assessment, patients were considered as affected (MSCI group) or not (MS group) by cognitive impairment. We analysed data comparing MSCI patients matched by sex, age (±5years) and e…

qEEG MS power spectrum analysis Cognitive impairmentmultiple sclerosis quantitative EEG cognitive impairmentSettore MED/26 - NeurologiaSettore BIO/09 - Fisiologia
researchProduct

Are paradoxical intensity-dependent effects of 5Hz rTMS train in motor cortex of migraine with aura patients evidence of abnormal homeostatic plastic…

2010

rTMS motor cortex homeostatic plastictySettore MED/26 - NeurologiaSettore BIO/09 - Fisiologia
researchProduct

INFLUENCE OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS) ON ACTION TREMOR IN MULTIPLE SCLEROSIS PATIENTS

2014

rTMSMultiple sclerosiSettore MED/26 - Neurologiatremor
researchProduct

Skala Niesprawności Neurologicznej Szpitala Guy jako istotne narzędzie do oceny objawów występujących u osób z SM

2017

Skala Niesprawności Neurologicznej Szpitala Guy (GNDS, The Guy’s Neurological Disability Scale) jest istotnym narzędziem służącym do pomiaru niepełnosprawności u osób ze stwardnieniem rozsianym. Służy ona do określenia poziomu funkcjonowania w dwunastu ważnych obszarach. Celem obecnych badań było opracowanie polskiej wersji językowej skali GNDS i sprawdzenie jej trafności, rzetelności oraz przydatności do oceny niepełnosprawności występującej u osób ze stwardnieniem rozsianym. Grupę badaną stanowiło 175. pacjentów z rozpoznaniem stwardnienia rozsianego. W badaniu wykorzystano Rozszerzoną Skalę Niewydolności Ruchowej – EDSS, Skalę Niesprawności Neurologicznej Szpitala Guy – GNDS, Skalę Akcep…

rehabilitacjadiagnostic techniquesThe Guy’s Neurological Disability Scaleneurologic examinationneuropsychologiabadanie neurologiczneSkala Niesprawności Neurologicznej Szpitala Guynarzędzia diagnostycznestwardnienie rozsianesclerosis multiplexrehabilitationNiepełnosprawność - Zagadnienia, Problemy, Rozwiązania
researchProduct

Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection

2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with several neurological disorders including headache, facial palsy, encephalitis, stroke, demyelinating disorders. The present report will discuss cases of multiple sclerosis (MS) onset and relapse both beginning early after SARS-CoV-2 infection. In both cases, magnetic resonance imaging (MRI) showed widespread bilateral subcortical and periventricular active lesions. Serum IgG against SARS-CoV-2 Spike antigens confirmed seroconversion with titers that are considered not definitely protective against possible reinfection. We hypothesize that SARS-CoV-2 infection, as previously reported for other vir…

relapseSettore MED/07 - Microbiologia E Microbiologia ClinicaonsetvirusesfungiRCOVID-19Case ReportNeurosciences. Biological psychiatry. Neuropsychiatrymultiple sclerosisRC31-1245vaccine.multiple sclerosivaccineMedicineSettore MED/26 - NeurologiaNeurology (clinical)Internal medicineRC321-571Neurology International
researchProduct

Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatment

2022

Aims: To evaluate how improved treatment adherence with a lower-frequency regimen/treatment of intramuscular (IM) IFN beta-1a impacts therapeutic effectiveness in relapsing-remitting multiple sclerosis (MS) patients switching from a higher-frequency injectable regimen/treatment. Patients & methods: Italian patients with relapsing-remitting MS and prior poor adherence to high-frequency injectable treatments (n = 181) were followed for 24 months after starting IM IFN beta-1a. Results: During the study, 97.4% of patients were treatment adherent; 22.1% of patients reported a relapse. The estimated probability of remaining relapse-free after 2 years was 78%. A high dropout rate (52.5%) led t…

relapsesMultiple Sclerosis Relapsing-RemittingTreatment Outcomequality of lifeRecurrenceHumansSettore MED/26 - NeurologiaInterferon-betaNeurology (clinical)multiple sclerosistreatment adherenceInterferon beta-1aintramuscular interferon beta-1aNeurodegenerative Disease Management
researchProduct

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multi…

2018

BACKGROUND: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. METHODS: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. RESULTS: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS tre…

safetymedicine.medical_specialtydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide; pharmacology; neurology; neurology (clinical)Populationefficacylcsh:RC346-429Disease activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineTeriflunomideteriflunomideMedicine030212 general & internal medicineno evidence of disease activity 3educationlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyeducation.field_of_studydimethyl fumarateDimethyl fumaratebusiness.industryMultiple sclerosismedicine.diseasechemistryRelapsing remittingNeurologySettore MED/26 - NeurologiaReal wordNeurology (clinical)business030217 neurology & neurosurgerydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide
researchProduct

PECULIARE EVOLUZIONE DELLA SEMEIOTICA NEURORADIOLOGICA DI UN CASO DI MALATTIA DEMIELINIZZANTE CON LESIONI PSEUDOTUMORALI

2013

SCOPO DEL LAVORO Presentiamo un caso di una paziente di 24 anni che giunge alla nostra attenzione per la comparsa di disartria come quadro clinico d’esordio di una forma aggressiva di malattia demielinizzante di cui si valuta l’atipica evoluzione neuroradiologica delle lesioni pseudotumorali che la caratterizzano e le possibili diagnosi differenziali. MATERIALI E METODI La paziente dopo una prima valutazione in PS è stata sottoposta a TC encefalo, ricoverata presso l’U.O. di Neurologia, sottoposta a controlli RM seriati (anche con tecniche avanzate); durante la degenza è stata inoltre effettuata una biopsia stereotassica. RISULTATI La TC ha rilevato almeno tre lesioni ipodense: a sinistra…

sclerosi multipla lesioni pseudotumorali lesioni stroke-likeSettore MED/27 - NeurochirurgiaSettore BIO/14 - FarmacologiaSettore MED/37 - NeuroradiologiaSettore MED/26 - NeurologiaSettore MED/08 - Anatomia PatologicaSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Sequenziamento temporale ed elaborazione neurale: una prospettiva psicofisiologica

2011

sicofisiologicaSequenziamentoSettore MED/26 - Neurologiaelaborazione neurale
researchProduct

ALS-RELATED FUS PROTEIN IS MISLOCALIZED TO CYTOPLASM AND RECRUITED INTO STRESS GRANULES IN FIBROBLASTS OF ASYMPTOMATIC FUS P525L MUTATION CARRIERS

Symptoms onset in Amyotrophic Lateral Sclerosis (ALS) occur when over 70% of motor neurons is already lost, suggesting a relatively long pre-symptomatic phase. The description of several genes linked to ALS (e.g., SOD1, FUS, TARDP, C9orf72) has now allowed identification of pre-symptomatic carriers. These pre-symptomatic (or even preclinical) carriers can be followed up with the aim to identify the very early clinical disease-related changes or a valuable biomarker. These efforts seem at present the best approach for the implementation of an early symptomatic therapy or for the disease prevention. In this work, we studied the expression of FUS protein in cultured skin fibroblasts from pre-s…

stress granuleshuman fibroblastsFUS P525L carriersSettore MED/26 - NeurologiaALScytoplasmic FUS expressionSettore BIO/09 - Fisiologia
researchProduct